QTORIN rapamycin 3.9 percent gel

Name: QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: American hospital formulary service (AHFS), or other drug classification
Published: 2026-09-14T15:39:06-04:00

Microcystic lymphatic malformations

Manufacturer: Palvella Therapeutics
Regulatory submission: NDA submitted August 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

American hospital formulary service (AHFS), or other drug classification

1 evidence topic · 1 source

Drug class

“rapamycin, a mammalian target of rapamycin (mTOR) inhibitor.” (opens the source at this quote in a new tab)

Product-specific AHFS classification

No evidence found.